Subcribe to Mid-day Gold with just Rs. 899 /Year

Home > News > India News > Article > DGCI panel approve Covovax EUA for 7 11 age group

DGCI panel approve Covovax EUA for 7-11 age group

Updated on: 25 June,2022 12:34 PM IST  |  New Delhi
IANS |

The Subject Expert Committee of Drugs Controller General Of India has recommended Serum Institute of India’s (SII) vaccine Covovax for children in the age group of 7-11 years

DGCI panel approve Covovax EUA for 7-11 age group

Representational image. Pic/iStock


Drugs Controller General of (DCGI) India on Friday recommended Emergency Use Authorisation (EUA) for Serum Institute of India’s Covovax vaccine for children aged 7-11, a source on Friday.


“The Subject Expert Committee of Drugs Controller General Of India has recommended Serum Institute of India’s (SII) vaccine Covovax for children in the age group of 7-11 years,” said the source.



The expert panel recommendation has been sent to the DCGI for final approval.


Also read: Mira Bhayander: MBMC reports 341 Covid cases, active caseload at 463

However, DGCI will review the recommendation before nodding for final approval. The expert panel in its last meeting in April had sought more information from Serum Institute over the application, as per the source.

India’s drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28, 2021, and in the 12-17 age group with certain conditions on March 9.

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

Register for FREE
to continue reading !

This is not a paywall.
However, your registration helps us understand your preferences better and enables us to provide insightful and credible journalism for all our readers.

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK